-
-
-
-
-
-
-
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
-
-
-
-
-
-
-
Zymeworks Outlines Strategic Priorities and Outlook for 2026
-
-
-
-
-
-
-
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
-
-
-
-
-
-
-
Zymeworks (ZYME) Announces Appointment of Derek J. Miller to its Board of Directors
-
-
-
-
-
-
-
Zymeworks (ZYME) Gains as Would-Be Suitor All Blue Capital Names Medical Advisor, Sends Letter Demanding Takeover Talks
-
-
-
-
-
-
-
Exelixis (EXEL) In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
-
-
-
-
-
-
-
Pre-Open Movers 04/24: (EVLV) (SANM) (WFT) Higher; (EPZM) (WAT) (MMM) Lower (more...)
-
1,156,141 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

